Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

1.695 +0.135 (+8.65%)
Streaming Delayed Price Updated: 12:35 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eledon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence ↗
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Expert Ratings for Eledon Pharma ↗
 
Via Benzinga
News headline image
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023 ↗
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive ↗
Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ... 
Via Benzinga
News headline image
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗
 
Via Benzinga
News headline image
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
Results from study published in Science Translational Medicine support further clinical development of tegoprubart (AT-1501) as a potential agent to promote kidney allograft survival and function in... 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
Trial to assess potential of tegoprubart-based immunosuppression to improve graft function compared to tacrolimus-based immunosuppression 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.